CLAIMS

1. A solid, oral pharmaceutical composition comprising a plurality of particles, each comprising:

a core comprising hydroxypropyl methylcellulose and microcrystalline cellulose, and a therapeutic amount of a central nervous system stimulant and at least one pharmaceutically acceptable excipient;

a sustained release layer enclosing the core, wherein the sustained release layer comprises dibutyl sebacate, ethyl cellulose, hydroxypropyl cellulose, and magnesium stearate; and

a delayed release layer enclosing the sustained release layer, wherein the delayed release layer comprises dibutyl sebacate, methacrylic acid copolymer Type B, monoglycerides, diglycerides and polysorbate 80,

wherein the composition provides a 4 to 12 hour period during which no more than 10% of the central nervous system stimulant is released when measured by the USP Apparatus I in which the composition is placed in 700 ml aqueous solution of 0.1N HCl pH 1.1, for up to 2 hours followed by 2-6 hr in sodium phosphate buffer at pH 6.0; followed by 6-20 hr in sodium phosphate buffer, pH 7.2 at 37°C ± 0.5°C.

2. The solid, oral pharmaceutical composition of claim 1, wherein the in vitro dissolution rate of the dosage form is between 0 and 10% drug released after 8 hours, between 2 and 30% released after 10 hours, between 15 and 60% released after 12 hours and between 45% and 95% released after 15 hours, and wherein the amount of drug released each hour increases from the period between 20% released and 65% released when measured by the USP Paddle Method at 75 rpm in 750 ml aqueous solution of 0.1N HCl for two hours followed by phosphate buffered solution at pH 6.8 and 37°C ± 0.5°C.

3. The solid, oral pharmaceutical composition of claim 1, wherein the in vitro dissolution rate of the dosage form is between 0 and 10% drug released after 6 hours, between 15 and 28% released after 10 hours, between 40 and 60% released after 12 hours and between 80% and 95% released after 15 hours, and wherein the amount of active ingredient released per each hour increases from the period between 20% released and 65% released, when measured by the USP Apparatus I in which the composition is placed in 700 ml aqueous solution of 0.1N HCl pH 1.1, for up to 2 hours followed by 2-6hr in sodium phosphate buffer at pH 6.0; followed by 6-20 hr in sodium phosphate buffer, pH 7.2 at 37°C ± 0.5°C.

4. The solid, oral pharmaceutical composition of any one of claims 1-3, wherein no more than 10% of the agent is released within 6 hours and no more than 50% of the agent is released within 12 hours when placed in aqueous solution of 0.1N HCl for two hours followed by phosphate buffered solution at pH 6.8 and 37°C ± 0.5°C, and wherein, when the composition is administered to a human, a plot of plasma concentration versus time after administration exhibits a maximum between 12 and 20 hours after administration.

5. The solid, oral pharmaceutical composition of any one of claims 1-4, wherein the core comprises amphetamine, dextroamphetamine, methylphenidate, or a pharmaceutical salt of any thereof.

6. A solid, oral pharmaceutical composition of any one of claims 1-7, comprising a therapeutic amount of a central nervous system stimulant wherein the composition, when orally administered to a human, provides a delayed release of the central nervous system stimulant from 4 to 12 hours and a maximum serum concentration (C_{max}) from 10 to 16 hours after administration.

7. The solid, oral pharmaceutical composition of claim 6, wherein the serum area under the curve at 6 hours (AUC_{0-6}) after administration is less than 2% of total $AUC_{0-\infty}$.

8. The solid, oral pharmaceutical composition of claim 6 or claim 7, wherein the serum area under the curve at 10 hours (AUC_{0-10}) after administration is less than 7% of total $AUC_{0-\infty}$.

9. A water soluble capsule containing the solid, oral pharmaceutical composition of any one of claims 1 to 8 and providing a single dose of the solid, oral pharmaceutical composition.

10. Use of a composition or capsule of any preceding claim for manufacture of a medicament for treatment of a subject having attention deficit disorder, attention deficit hyperactivity disorder, excessive daytime sleepiness, major depressive disorder, bipolar depression, negative symptoms in schizophrenia, chronic fatigue, narcolepsy, fatigue associated with chemotherapy or binge eating disorder.

.